Gilead GILD
Gilead is a biopharmaceutical company that develops and commercializes innovative therapies for HIV, oncology, and inflammatory diseases. Gilead presents a solid financial profile with an operating margin of 33.68% and an ROIC of 26.95%, although its negative ROE (-20.68%) and a PEG of 2.24 suggest growth is already priced in. HIV concentration is a risk to watch, but cash generation (FCF yield 5.22%) and a moderate payout (43.40%) provide a stable base.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Gilead is a biopharmaceutical company that develops and commercializes innovative therapies for HIV, oncology, and inflammatory diseases. Gilead presents a solid financial profile with an operating margin of 33.68% and an ROIC of 26.95%, although its negative ROE (-20.68%) and a PEG of 2.24 suggest growth is already priced in. HIV concentration is a risk to watch, but cash generation (FCF yield 5.22%) and a moderate payout (43.40%) provide a stable base.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.5 |
| Quality / Moat | 7.2 |
| Valuation | 5.0 |
| Growth | 6.8 |
| Dividend | 7.0 |
| Momentum | 7.2 |
| Risk & Context | 8.3 |
OVERALL SCORE: 6.9/10
Context and risks
Gilead operates in the U.S. pharmaceutical sector, subject to regulatory pressure on drug pricing (IRA). Although its HIV portfolio is less exposed than others, regulatory pricing uncertainty is a relevant sector risk.
News considered in the analysis
- Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income? — Listículo comparativo sin información nueva sobre Gilead.
- Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? — Listículo comparativo sin información nueva sobre Gilead.
- Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification? — Listículo comparativo sin información nueva sobre Gilead.
- Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? — Listículo comparativo sin información nueva sobre Gilead.
- Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know — Movimiento de precio rutinario sin información fundamental nueva.
Verdict: Hold; valuation is reasonable (forward P/E 15.26) and fundamentals are solid, but HIV concentration and regulatory pressure limit upside potential.
Main risk: High revenue concentration in HIV exposes Gilead to significant risk if a competitor launches a superior therapy or if regulatory pricing pressure intensifies.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →